Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Recruiting · NCT05877963 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Relapsing Multiple Sclerosis | Recruiting | Phase 3 | 2026-09-21 | NCT05877963 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| TG Therapeutics, Inc. | 16 |
49 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.